"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 4 | 4 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 5 | 2 | 7 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 4 | 4 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 3 | 4 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Niture S, Tricoli L, Qi Q, Gadi S, Hayes K, Kumar D. MicroRNA-99b-5p targets mTOR/AR axis, induces autophagy and inhibits prostate cancer cell proliferation. Tumour Biol. 2022; 44(1):107-127.
-
Chakraborty S, Utter MB, Frias MA, Foster DA. Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin. Cancer Lett. 2021 12 01; 522:164-170.
-
Hao Q, Wang P, Dutta P, Chung S, Li Q, Wang K, Li J, Cao W, Deng W, Geng Q, Schrode K, Shaheen M, Wu K, Zhu D, Chen QH, Chen G, Elshimali Y, Vadgama J, Wu Y. Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020 12 11; 11(12):1052.
-
Venugopal SV, Caggia S, Gambrell-Sanders D, Khan SA. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells. Prostate. 2020 04; 80(5):412-423.
-
Yang X, Hei C, Liu P, Li PA. Prevention of post-ischemic seizure by rapamycin is associated with deactivation of mTOR and ERK1/2 pathways in hyperglycemic rats. Biochem Biophys Res Commun. 2019 11 26; 520(1):47-53.
-
Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2020 10; 3(5):687-694.
-
Basar MA, Williamson K, Roy SD, Finger DS, Ables ET, Duttaroy A. Spargel/dPGC-1 is essential for oogenesis and nutrient-mediated ovarian growth in Drosophila. Dev Biol. 2019 10 15; 454(2):97-107.
-
Hu LT, Zhu BL, Lai YJ, Long Y, Zha JS, Hu XT, Zhang JH, Chen GJ. HMGCS2 promotes autophagic degradation of the amyloid-? precursor protein through ketone body-mediated mechanisms. Biochem Biophys Res Commun. 2017 04 29; 486(2):492-498.
-
Alshaman R, Truong L, Oyekan A. Role of mechanistic target of rapamycin (mTOR) in renal function and ischaemia-reperfusion induced kidney injury. Clin Exp Pharmacol Physiol. 2016 Nov; 43(11):1087-1096.
-
Liu P, Yang X, Hei C, Meli Y, Niu J, Sun T, Li PA. Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals Is Associated with Suppressions of mTOR and ERK1/2 Signaling. Int J Biol Sci. 2016; 12(8):1032-40.